Amarin Corporation plc (Nasdaq: AMRN)

https://www.amarincorp.com

Amarin is committed to improving the lives of patients suffering from central nervous system and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs.

Amarin's CNS development pipeline includes the recently acquired myasthenia gravis clinical program and preclinical programs in neuromuscular, neuronal degenerative and inflammatory diseases; Miraxion for Huntington's disease; two programs in Parkinson's disease; one in epilepsy; and one in memory and cognition. Amarin is initiating a series of cardiovascular preclinical and clinical programs to capitalize on the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin also has a proprietary lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain that can be leveraged in a wide range of disease applications for its own product pipeline or with potential partners. *

	Start	2001-01-04 existent
	Industry	pharmaceutical

	Region	London, Greater London
	Country	United Kingdom (GB)
	Street	7 Curzon Street
	City	W1J 5HG London
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	USD
	Profit	-38,197,000 (2007-12-31)
	Cash	18,303,000 (2007-12-31)

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)